Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection

Journal of the International Association of Physicians in AIDS Care

Volumn 11, Issue 5, 2012, Pages 273-276

  Ahmed, Rabia ^a   Cooper, Ryan ^a   Foisy, Michelle ^a   Der, Evelina ^b   Kunimoto, Dennis ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

isoniazid; pharmacokinetics; rifamycins

Indexed keywords

ISONIAZID; RIFAMPICIN; RIFAMYCIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; CANADA; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEASUREMENT; MIXED INFECTION; PRIORITY JOURNAL; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; BODY MASS INDEX; BODY WEIGHT; COINFECTION; CROSS-SECTIONAL STUDIES; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFABUTIN; RIFAMPIN; TUBERCULOSIS;

EID: 84867026201     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109712454454     Document Type: Article

References (19)

1. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis. 2004 ; 38 (2). 280-283
2. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep. 2002 ; 51 (10). 214-215
3. el-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short course re-treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn community programs for clinical research on AIDS (CPCRA) and the AIDS clinical trials group (ACTG). Clin Infect Dis. 1998 ; 26 (5). 1148-1158
4. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999 ; 353 (9167). 1843-1847
5. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentration associated with outcome of tuberculosis treatment with once weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003 ; 167 (10). 1341-1347
6. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005 ; 40 (10). 1481-1491
7. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002 ; 62 (15). 2169-2183
8. McIlleron H, Rustomjee R, Vaheda M, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012 ; 56 (6). 3232-3238
9. Holland DP, Hamilton CD, Weintrob AC, et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy. 2009 ; 29 (5). 503-510
10. Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005 ; 41 (4). 461-469
11. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-Infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009 ; 48 (12). 1685-1694
12. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest. 1998 ; 113 (5). 1178-1183
13. Mehta JB, Shantaveerapa H, Byrd RP, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest. 2001 ; 120 (5). 1520-1524
14. Morehead RS. Delayed death from pulmonary tuberculosis: unsuspected subtherapeutic drug levels. South Med J. 2000 ; 93 (5). 507-510
15. Gilljam M, Berning SE, Peloquin CA, Strandvik B, Larsson LO. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J. 1999 ; 14 (2). 347-351
16. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother. 2009 ; 10 (3). 381-401
17. Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-Infected persons with tuberculosis. Clin Infect Dis. 2005 ; 41 (11). 1638-1647
18. Boulanger C, Hollender E, Farrell F, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009 ; 49 (9). 1305-1311
19. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007 ; 51 (7). 2546-2551